FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer's Disease: Where Are We Now? — Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by decreased amyloid-beta (Aβ) clearance, enhanced Aβ aggregation, an increased risk of amyloid-related imaging abnormalities (ARIA), and...

Evidence span

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer's Disease: Where Are We Now? — Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by decreased amyloid-beta (Aβ) clearance, enhanced Aβ aggregation, an increased risk of amyloid-related imaging abnormalities (ARIA), and...

From Higgins M et al. 2026, International journal of molecular sciences

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

Homo sapiens

Conditions

Blood-Brain Barrier; Animals; Humans; Alzheimer Disease; Antibodies, Monoclonal — International journal of molecular sciences 2026

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required